Continuous care. Human connection.
Continuous remote monitoring and behavioural support for NHS paediatric and adult obesity pathways — between clinic appointments.
“Having access to live progress allows us to intervene in real time, reaching out to reflect on progress and overcome challenges.”— Jayne, CEW Clinical Nurse Specialist, UK
Who we work with
Clinical effect
Evira strengthens the alliance with families through regular feedback and support. In a Swedish pragmatic trial, the larger reduction in BMI Z-score after one year was maintained at three years.
Average BMI Z-score over three years for the digi-physical treatment group and matched standard-treatment group, adjusted for sex, age and degree of obesity at treatment start. This Swedish study is not an NHS service outcome.
Read the peer-reviewed three-year study →Evira in the NHS
Evira is used alongside different models of specialist CEW care — from regional hubs and local spokes to home-first and hybrid pathways.
Explore public evidence, implementation experience and service outcomes from NHS teams across England.
NHS CEW services featured
Hubs + spokes
NHS England regions
Cases span published Evira evaluations, service outcomes, pathway redesign and real-world implementation.
Find your service
Explore the priorities, care model and practical next steps for your team.
A family-centred approach to obesity care, from community services through to specialist treatment.
Support children and young people with complex needs, alongside your specialist MDT.
Build family engagement and ongoing follow-up into your local childhood obesity pathway.
Connect monitoring and behavioural support across adult obesity treatment.
Tier 2 programmes, medication-supported care, transition services, learning disability services and research collaborations all build on the same continuous-care model.
The Evira approach
A meaningful change in a patient's progress can happen long before their next visit. Evira connects home monitoring with clinical judgement, in three steps.

A numberless smart scale and app help patients and families follow progress against an individual treatment goal.

The clinical dashboard surfaces traffic-light alerts and progress across the caseload — 2–4 minutes per patient per week.

In-app messaging and proactive outreach let the team reflect on progress and agree the next step together — between reviews.
Alongside appointments, with review frequency and clinical responsibility agreed by your service. Evira supports treatment delivered by your team; it is not a separate care provider.
In the CEW clinic
Specialist teams describe the difference as knowing sooner — and being able to act while it still matters.
Around 10% of children in UK CEW services using Evira are now also receiving GLP-1 medication. Evira provides the behavioural monitoring, dosing communication and lifestyle support that make pharmacotherapy more effective.
Learn about Evira & GLP-1 →DTAC, DSPT, Cyber Essentials, DCB0129, CE marked, ICO registered. We provide complete evidence packs to accelerate your procurement.
Digital Technology Assessment Criteria.
Clinical risk management standards.
Data Security & Protection Toolkit.
Medical device, class I.
Certified for Cyber Essentials.
UK GDPR compliant.
We can provide a complete DTAC evidence pack, help you complete DPIA templates, and supply data processing agreements. View full compliance documentation →
Evidence across settings
Peer-reviewed research, NHS service evidence and operational data each answer a different question.
Sweden
Peer-reviewed researchDoes it work?
A Swedish pragmatic trial found that the larger BMI z-score reduction achieved at one year was maintained at three years.
NHS England
Service evaluation / customer evidenceDoes it work in the NHS?
NHS customer cases document implementation, pathway experience and published service outcomes without presenting them as clinical trials.
Abu Dhabi
Peer-reviewed international evidenceDoes it translate to a second setting?
In a 2026 study, adjusted 26-week BMI z-score change was −0.20 in both Abu Dhabi and Stockholm, meeting the predefined non-inferiority criterion.
The Abu Dhabi study provides early evidence of transferability. Non-retention was higher in Abu Dhabi than in Stockholm, and the findings should not be interpreted as universal generalisability.
By shifting care from clinic-based to digital-first delivery, Evira reduces environmental impact across the pathway.
Home-based monitoring and digital follow-up replace many in-person visits — fewer journeys for patients and staff.
The numberless scale is durable, reusable, and refurbishable when returned. Several household members share one device.
Less reliance on printed materials. Digital communication replaces letters and paper forms.
Clinicians can review dashboards and reply to messages remotely, reducing staff travel where appropriate.
A scalable solution for long-term weight management — built to support ICB and Trust priorities in prevention, inequalities, sustainability and cost efficiency.
Book a demonstration